Nautilus Biotechnolgy

NAUT

Market cap $139M

Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 1:50 PM EDT Company Participants Sujal Patel - Co-Founder, CEO, President, Secretary & Director Conference Call Participants Yuko Oku - Morgan Stanley, Research Division Presentation Yuko Oku Equity Analyst Hello. Hi. My name is Yuko Oku, and I work on the Life Science Tools and Diagnostics team at Morgan Stanley.

SEATTLE, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the following investor conferences.

Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q2 2025 Earnings Call July 31, 2025 8:30 AM ET Company Participants Anna Mowry - CFO & Treasurer Parag Mallick - Co-Founder, Chief Scientist & Director Sujal M. Patel - Co-Founder, CEO, President, Secretary & Director Conference Call Participants Daniel Gregory Brennan - TD Cowen, Research Division Subhalaxmi T.

SEATTLE, July 31, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2025.

SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the second quarter 2025 before market open on Thursday, July 31, 2025.

Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ET Company Participants Ji-Yon Yi - Head, Investor Relations Sujal Patel - Co-Founder & Chief Executive Officer Parag Mallick - Co-Founder & Chief Scientist Anna Mowry - Chief Financial Officer Conference Call Participants Elizabeth Kolsky - Goldman Sachs Operator Good day, and thank you for standing by. Welcome to the Nautilus First Quarter 2025 earnings conference call.

Nautilus Biotechnology, Inc. faces reflexivity risks and macroeconomic challenges, but its commercial plan starts next year with substantial cash reserves. Trading below cash value, Nautilus' patents and bio-informatics platform are not being given too much credit by markets. Although, they seem to expect that company to be minimally viable once they have an additional $30 million of cash, which still may not be enough depending on commercial costs.

Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Ji-Yon Yi - Head, Investor Relations Sujal Patel - Co-Founder & Chief Executive Officer Parag Mallick - Co-Founder & Chief Scientist Anna Mowry - Chief Financial Officer Conference Call Participants Yuko Oku - Morgan Stanley Subbu Nambi - Guggenheim Securities Dan Brennan - TD Cowen Will Ortmayer - Goldman Sachs Operator Good day, and thank you for standing by. Welcome to the Nautilus Fourth Quarter and Full Year 2024 Earnings Conference Call.

Nautilus Biotechnology has laid off about 16% of its workforce, reducing its headcount to 133 employees and helping provide a cash runway that extends into 2027.

Dr. Mallick to be inducted into the Academy for Radiology and Biomedical Imaging Research's esteemed Council of Distinguished Investigators for his outstanding contributions to medical imaging Dr. Mallick to be inducted into the Academy for Radiology and Biomedical Imaging Research's esteemed Council of Distinguished Investigators for his outstanding contributions to medical imaging